CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples.
Fuente:
PubMed
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Bioanalysis
2025
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1868266141778968576 |
|---|---|
| author | Chen, Xiaoqing Ye, Qiaoyuan Liang, Qingle Li, Jiahui Huang, Yumei Xia, Qiyuan Xiao, Jianrong Liao, Chenyu Lau, Cia-Hin Zhu, Haibao |
| author_facet | Chen, Xiaoqing Ye, Qiaoyuan Liang, Qingle Li, Jiahui Huang, Yumei Xia, Qiyuan Xiao, Jianrong Liao, Chenyu Lau, Cia-Hin Zhu, Haibao Chen, Xiaoqing Ye, Qiaoyuan Liang, Qingle Li, Jiahui Huang, Yumei Xia, Qiyuan Xiao, Jianrong Liao, Chenyu Lau, Cia-Hin Zhu, Haibao |
| collection | PubMed - marine biology |
| contents | CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples. Chen, Xiaoqing Ye, Qiaoyuan Liang, Qingle Li, Jiahui Huang, Yumei Xia, Qiyuan Xiao, Jianrong Liao, Chenyu Lau, Cia-Hin Zhu, Haibao Humans MicroRNAs CRISPR-Cas Systems Biomarkers, Tumor Mutation Tumor-associated genetic markers are useful for early cancer screening, diagnosis, and treatment monitoring. However, traditional detection methods are complex in operation procedures, time-consuming, and the equipment costs are expensive. CRISPR/Cas systems are becoming emerging detection tools for tumor detection due to their programmability, rapid reaction, high targeting specificity, and the ability to amplify the signals. CRISPR/Cas has made breakthroughs in the detection of tumor-associated genetic materials including gene mutations, DNA methylation, miRNA, lncRNA, and circRNA detection. Herein, we critically discuss these advancements and describe the key concepts of each CRISPR/Cas system for detecting tumor-associated genetic materials. The significance of these tumor-associated genetic materials in cancer diagnosis and prognosis is highlighted. |
| format | Artículo científico |
| id | pubmed_41064997 |
| institution | PubMed |
| language | en |
| publishDate | 2025 |
| publisher | Bioanalysis |
| record_format | pubmed |
| spellingShingle | CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples. Chen, Xiaoqing Ye, Qiaoyuan Liang, Qingle Li, Jiahui Huang, Yumei Xia, Qiyuan Xiao, Jianrong Liao, Chenyu Lau, Cia-Hin Zhu, Haibao Humans MicroRNAs CRISPR-Cas Systems Biomarkers, Tumor Mutation CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples. Chen, Xiaoqing Ye, Qiaoyuan Liang, Qingle Li, Jiahui Huang, Yumei Xia, Qiyuan Xiao, Jianrong Liao, Chenyu Lau, Cia-Hin Zhu, Haibao Humans MicroRNAs CRISPR-Cas Systems Biomarkers, Tumor Mutation Tumor-associated genetic markers are useful for early cancer screening, diagnosis, and treatment monitoring. However, traditional detection methods are complex in operation procedures, time-consuming, and the equipment costs are expensive. CRISPR/Cas systems are becoming emerging detection tools for tumor detection due to their programmability, rapid reaction, high targeting specificity, and the ability to amplify the signals. CRISPR/Cas has made breakthroughs in the detection of tumor-associated genetic materials including gene mutations, DNA methylation, miRNA, lncRNA, and circRNA detection. Herein, we critically discuss these advancements and describe the key concepts of each CRISPR/Cas system for detecting tumor-associated genetic materials. The significance of these tumor-associated genetic materials in cancer diagnosis and prognosis is highlighted. |
| title | CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples. |
| topic | Humans MicroRNAs CRISPR-Cas Systems Biomarkers, Tumor Mutation |
| url | https://pubmed.ncbi.nlm.nih.gov/41064997/ |